Clinical Trial

Immune Biomarker Study for Head and Neck Cancer

Study acronym: ImmunBio-KHT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 17, 2023 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this prospective non-interventional multi-center trial is to study the prognostic value of intratumoral and systemic immune biomarkers in newly diagnosed non-metastatic head and neck cancer. Furthermore, the local immunological processes in the tumor will be correlated with the systemic immune status determined in the peripheral blood to identify prognostic immune signatures. In addition, tumor organoids will be generated ex vivo for functional biological analyses. The main objective is to create a prognostic score determined by clusters based on tumor immunologic criteria.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-11; most recent amendment 2023-05-16.
Status change: Not Yet Recruiting → Recruiting 2023-01-23
Trial Details
NCT Number NCT05375266
Lead Sponsor University of Erlangen-Nürnberg Medical School
Collaborators: University Hospital Erlangen, University Hospital Regensburg, University Hospital Augsburg
Conditions Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer, Laryngeal Cancer
Enrollment 1,100 participants
Start Date 2022-05-16
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-17